Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy Using a Modified Intensive Treat and Extend Regime to a Fixed Dosing Regimen

Next Previous
X
Search
Trial Profile

An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy Using a Modified Intensive Treat and Extend Regime to a Fixed Dosing Regimen

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Jul 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Polypoidal choroidal vasculopathy
  • Focus Therapeutic Use

    • Most Recent Events

    • 01 Jul 2022 Primary endpoint (Mean Change in Best Corrected Visual Acuity (BCVA) has been met according to the results published in the British Journal of Ophthalmology
    • 01 Jul 2022 Results comparing the the efficacy of aflibercept using a personalised versus fixed regimen in treatment-naive participants with polypoidal choroidal vasculopathy (PCV) published in the British Journal of Ophthalmology
    • 01 Jan 2022 Results of Post hoc analysis assessing whether optical coherence tomography can determine polypoidal lesion perfusion in polypoidal choroidal vasculopathy eyes after 12 months of aflibercept monotherapy, published in the Retina

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top